Levodopa: the story so far

Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease

Church, F. (2021) · Biomolecules · doi:10.3390/biom11040612 · Cited by 303 · see citing works

Levodopa in Parkinson’s Disease: Current Status and Future Developments

Tambasco, N., Romoli, M., & Calabresi, P. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170510143821 · Cited by 236 · see citing works

Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders

Bahadur, S., Pardhi, D. M., Rautio, J., Rosenholm, J. M., & Pathak, K. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121230 · Cited by 172 · see citing works

Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system

Wang, C., Xue, Y., Markovic, T., Li, H., Wang, S., Zhong, Y., Du, S., Zhang, Y., Hou, X., Yu, Y., et al. (2025) · Nature Materials · doi:10.1038/s41563-024-02114-5 · Cited by 171 · see citing works

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020

McFarthing, K., Buff, S., Rafaloff, G., Dominey, T., Wyse, R. K. H., & Stott, S. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202128 · Cited by 138 · see citing works

Neuroprotective effects of fingolimod in mouse models of Parkinson's disease

Zhao, P., Yang, X., Yang, L., Li, M., Wood, K., Liu, Q., & Zhu, X. (2016) · The FASEB Journal · doi:10.1096/fj.201600751r · Cited by 116 · see citing works

Current Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update

Prasad, E. M., & Hung, S. (2021) · Pharmaceuticals · doi:10.3390/ph14080717 · Cited by 112 · see citing works

Non‐Invasive Sweat‐Based Tracking of L‐Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration

Moon, J., Teymourian, H., De la Paz, E., Sempionatto, J. R., Mahato, K., Sonsa‐ard, T., Huang, N., Longardner, K., Litvan, I., & Wang, J. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202106674 · Cited by 103 · see citing works

Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer's, Parkinson's and Prion's

Nirale, P., Paul, A., & Yadav, K. S. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117394 · Cited by 103 · see citing works

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort

Eusebi, P., Romoli, M., Paoletti, F. P., Tambasco, N., Calabresi, P., & Parnetti, L. (2018) · npj Parkinson s Disease · doi:10.1038/s41531-018-0069-x · Cited by 98 · see citing works

The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications

Banks, W. A., Rhea, E. M., Reed, M. J., & Erickson, M. A. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101760 · Cited by 90 · see citing works

Levodopa in Mucuna pruriens and its degradation

Pulikkalpura, H., Kurup, R., Mathew, P. J., & Baby, S. (2015) · Scientific Reports · doi:10.1038/srep11078 · Cited by 86 · see citing works

Levodopa-loaded nanoparticles for the treatment of Parkinson's disease

van Vliet, E. F., Knol, M. J., Schiffelers, R. M., Caiazzo, M., & Fens, M. H. A. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.026 · Cited by 85 · see citing works

Closing the loop for patients with Parkinson disease: where are we?

Teymourian, H., Tehrani, F., Longardner, K., Mahato, K., Podhajny, T., Moon, J., Goud, K. Y., Sempionatto, J. R., Litvan, I., & Wang, J. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00674-1 · Cited by 77 · see citing works

Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients

Klietz, M., Greten, S., Wegner, F., & Höglinger, G. U. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00654-z · Cited by 62 · see citing works

Translational molecular imaging and drug development in Parkinson’s disease

Haider, A., Elghazawy, N. H., Dawoud, A., Gebhard, C., Wichmann, T., Sippl, W., Hoener, M. C., Arenas, E., & Liang, S. H. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00600-z · Cited by 59 · see citing works

Medicinal plants used by traditional medicine practitioners to boost the immune system in people living with HIV/AIDS in Uganda

Anywar, G., Kakudidi, E. K., Byamukama, R., Mukonzo, J., Schubert, A., & Oryem‐Origa, H. (2019) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2019.101011 · Cited by 53 · see citing works

Variations in the L-DOPA Content, Phytochemical Constituents and Antioxidant Activity of Different Germlines of Mucuna pruriens (L.) DC.

Rakesh, B., Bindu, K. H., & Nagella, P. (2021) · Asian Journal of Chemistry · doi:10.14233/ajchem.2021.23293 · Cited by 50 · see citing works

Discovery of 3-Arylcoumarin-tetracyclic Tacrine Hybrids as Multifunctional Agents against Parkinson?s Disease

Sashidhara, K. V., Modukuri, R. K., Jadiya, P., Rao, K. B., Sharma, T., Haque, R., Singh, D. K., Banerjee, D., Siddiqi, M. I., & Nazir, A. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500222g · Cited by 44 · see citing works

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease

Conti, V., Izzo, V., Russillo, M. C., Picillo, M., Amboni, M., Scaglione, C. L. M., Nicoletti, A. S. Q., Cani, I., Cicero, C. E., Bellis, E. D., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.909936 · Cited by 43 · see citing works

Identification ofN-Propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a New Anti-Parkinson's Agent Possessing a Dopamine D2and Serotonin 5-HT1ADual-Agonist Profile

Zhang, H., Ye, N., Zhou, S., Guo, L., Zheng, L. T., Liu, Z., Gao, B., Zhen, X., & Zhang, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200347t · Cited by 42 · see citing works

5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson’s disease and schizophrenia

Haleem, D. J. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000123 · Cited by 41 · see citing works

Comprehensive mass analysis for chemical processes, a case study on l -Dopa manufacture

Li, T., & Li, X. (2014) · Green Chemistry · doi:10.1039/c4gc00565a · Cited by 40 · see citing works

Nanomaterials as novel agents for amelioration of Parkinson’s disease

Wu, J., Cui, X., Ke, P. C., Mortimer, M., Wang, X., Bao, L., & Chen, C. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101328 · Cited by 37 · see citing works

The return of the lesion for localization and therapy

Joutsa, J., Lipsman, N., Horn, A., Cosgrove, G. R., & Fox, M. D. (2023) · Brain · doi:10.1093/brain/awad123 · Cited by 36 · see citing works

Vibrational spectral analysis of anti-neurodegenerative drug Levodopa: A DFT study

Edwin, B., & Joe, I. H. (2012) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2012.09.004 · Cited by 35 · see citing works

Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?

Salado-Manzano, C., Perpiñá, U., Straccia, M., Molina-Ruiz, F. J., Cozzi, E., Rosser, A., & Canals, J. M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00250 · Cited by 34 · see citing works

Induced Pluripotent Stem Cells for Treatment of Alzheimer’s and Parkinson’s Diseases

Yefroyev, D. A., & Jin, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020208 · Cited by 36 · see citing works

Wearable Electrochemical Sensors in Parkinson’s Disease

Asci, F., Vivacqua, G., Zampogna, A., D’Onofrio, V., Mazzeo, A., & Suppa, A. (2022) · Sensors · doi:10.3390/s22030951 · Cited by 29 · see citing works

Particulate levodopa nose-to-brain delivery targets dopamine to the brain with no plasma exposure

Dimiou, S., Lopes, R. M., Kubajewska, I., Mellor, R. D., Schlosser, C. S., Shet, M. S., Huang, H., Akcan, O., Whiteside, G. T., Schätzlein, A. G., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121658 · Cited by 28 · see citing works

Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug

Thiele, N. A., Kärkkäinen, J., Sloan, K. B., Rautio, J., & Huttunen, K. M. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.030 · Cited by 28 · see citing works

The Significance of Discovery Screening and Structure Optimization Studies

Osakwe, O. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802220-7.00005-3 · Cited by 25 · see citing works

Rapid analysis of medically relevant compounds in faba bean seeds using FAIMS and mass spectrometry

Purves, R. W., Zhang, H., Khazaeı, H., & Vandenberg, A. (2017) · International Journal for Ion Mobility Spectrometry · doi:10.1007/s12127-017-0226-7 · Cited by 25 · see citing works

Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson’s disease

Lenka, A., Maria, G. D., Lamotte, G. J., Bahroo, L. B., & Jankovic, J. J. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2091436 · Cited by 21 · see citing works

Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.

DeMaagd, G. A., & Philip, A. (2015) · PubMed Central · Cited by 21 · see citing works

Are ion channels potential therapeutic targets for Parkinson’s disease?

Daniel, N. H., Aravind, A., & Thakur, P. S. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.10.008 · Cited by 20 · see citing works

A review of MPTP-induced parkinsonism in adult zebrafish to explore pharmacological interventions for human Parkinson’s disease

Bagwell, E., & Larsen, J. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1451845 · Cited by 19 · see citing works

Levodopa does not change cerebral vasoreactivity in Parkinson's disease

Krainik, A., Maillet, A., Fleury, V., Sahin, M., Troprés, I., Lamalle, L., Thobois, S., Fraix, V., Villien, M., Warnking, J. M., et al. (2012) · Movement Disorders · doi:10.1002/mds.25267 · Cited by 19 · see citing works

Effects of systemic drugs on the development and progression of age-related macular degeneration

Grimes, K. R., Aloney, A., Skondra, D., & Chhablani, J. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.01.007 · Cited by 18 · see citing works

Neuromodulation in Parkinson’s disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach

Alam, M. R., & Singh, S. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01259-0 · Cited by 19 · see citing works

Combining Precursor-Directed Engineering with Modular Designing: An Effective Strategy for De Novo Biosynthesis of l -DOPA in Bacillus licheniformis

Xu, Y., Li, Y., Wu, Z., Lu, Y., Tao, G., Zhang, L., Ding, Z., & Shi, G. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00411 · Cited by 17 · see citing works

Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs

Thomas, C., Wurzer, L., Malle, E., Ristow, M., & Madreiter‐Sokolowski, C. T. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.905261 · Cited by 18 · see citing works

Plasmonic Sensing: Connecting the Dots

Chatterjee, H., Bardhan, D., Pal, S. K., Yanase, K., & Ghosh, S. K. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c00795 · Cited by 17 · see citing works

The Story of Levodopa

Bhattacharyya, K. (2022) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_474_21 · Cited by 16 · see citing works

An insight into the iPSCs-derived two-dimensional culture and three-dimensional organoid models for neurodegenerative disorders

Bhargava, A., Sandoval-Castellanos, A. M., Shah, S. S., & Ning, K. (2022) · Interface Focus · doi:10.1098/rsfs.2022.0040 · Cited by 15 · see citing works

Serum zinc deficiency could be associated with dementia conversion in Parkinson’s disease

Lee, J., Park, S., & Jang, W. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1132907 · Cited by 16 · see citing works

Current Small Molecule–Based Medicinal Chemistry Approaches for Neurodegeneration Therapeutics

Sanghai, N., Vuong, B., Berk, A. B., Afridi, M. S. K., & Tranmer, G. K. (2024) · ChemMedChem · doi:10.1002/cmdc.202300705 · Cited by 15 · see citing works

Cognitive Impairment in Alzheimer’s and Metabolic Diseases: A Catecholaminergic Hypothesis

Guzmán-Ramos, K. R., Osorio‐Gómez, D., & Bermúdez‐Rattoni, F. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.031 · Cited by 15 · see citing works

Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma

Li, Z., Li, X., He, X., Jia, X., Zhang, X., Lu, B., Zhao, J., Lü, J., Chen, L., Dong, Z., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.568459 · Cited by 14 · see citing works

Inhibition of α-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinson’s disease

Kim, S., Choi, J. G., Kim, S. W., Park, S. C., Kang, Y.-R., Park, D. S., Son, M., & Lee, C. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113637 · Cited by 13 · see citing works

Dopamine D1 receptor-agonist interactions: A mutagenesis and homology modeling study

Mente, S., Guilmette, E. R., Salafia, M. A., & Gray, D. L. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.03.079 · Cited by 13 · see citing works

Non‐Invasive Sweat‐Based Tracking of L‐Dopa Pharmacokinetic Profiles Following an Oral Tablet Administration

Moon, J., Teymourian, H., la Paz, E. D., Sempionatto, J. R., Mahato, K., Sonsa‐ard, T., Huang, N., Longardner, K., Litvan, I., & Wang, J. (2021) · Angewandte Chemie · doi:10.1002/ange.202106674 · Cited by 13 · see citing works

Bioengineered gut bacterium synthesizing levodopa alleviates motor deficits in models of Parkinson’s disease

Padhi, P., Abdalla, A., Schneider, B., Backes, N., Otto, A. A., Scheibe, I., Thomas, J. P., Khadse, G., Samidurai, M., Jochmans, A. K., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.10.005 · Cited by 12 · see citing works

“Blind men and an elephant”: The need for animals in research, drug safety studies, and understanding civilizational diseases

Anbalagan, S. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12364 · Cited by 12 · see citing works

Formation of Bioactive Tyrosine Derivatives during Sprouting and Fermenting of Selected Whole Grains

Canlı, M., Çelik, E. E., Kocadağlı, T., Kanmaz, E. Ö., & Gökmen, V. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c05064 · Cited by 11 · see citing works

In Silico Identification of Multi-Target Ligands as Promising Hit Compounds for Neurodegenerative Diseases Drug Development

Alov, P., Stoimenov, H., Lessigiarska, I., Pencheva, T., Tzvetkov, N. T., Pajeva, I. K., & Tsakovska, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113650 · Cited by 11 · see citing works

Selecting the Best Animal Model of Parkinson’s Disease for Your Research Purpose: Insight from in vivo PET Imaging Studies

Real, C. C., Binda, K. H., Thomsen, M. B., Lillethorup, T. P., Brooks, D. J., & Landau, A. M. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230216101659 · Cited by 11 · see citing works

L-DOPA Autoxidation: An Empirical Valence Bond Simulation of the Reactive Step

Prah, A., & Mavri, J. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c03002 · Cited by 10 · see citing works

Rigidity in Parkinson's Disease: The Objective Effect of Levodopa

Falletti, M., Asci, F., Zampogna, A., Patera, M., Pinola, G., Centonze, D., Hallett, M., Rothwell, J. C., & Suppa, A. (2025) · Movement Disorders · doi:10.1002/mds.30114 · Cited by 10 · see citing works

Imaging SERT Availability in a Rat Model of L-DOPA-Induced Dyskinesia

Walker, M., Kuebler, L., Goehring, C. M., Pichler, B. J., & Herfert, K. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01418-2 · Cited by 10 · see citing works

Neuroprotection in Parkinson Disease

Gonzalez‐Robles, C., Bandmann, O., & Schapira, A. H. V. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00793-z · Cited by 11 · see citing works

Surgical Management of Synucleinopathies

Sriram, S., Root, K. T., Chacko, K. M., Patel, A., & Lucke-Wold, B. P. (2022) · Biomedicines · doi:10.3390/biomedicines10102657 · Cited by 9 · see citing works

Protein aggregation-inhibition: a therapeutic route from Parkinson’s disease to sickle cell anemia

Martins, G. F., & Galamba, N. (2023) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2023.2201406 · Cited by 9 · see citing works

A Case of DNAJC12-Deficient Hyperphenylalaninemia Detected on Newborn Screening: Clinical Outcomes from Early Detection

Donnelly, C. M., Estrella, L., Ginevic, I., & Ganesh, J. (2024) · International Journal of Neonatal Screening · doi:10.3390/ijns10010007 · Cited by 8 · see citing works

Aberrant CpG Methylation Mediates Abnormal Transcription of MAO-A Induced by Acute and Chronic l-3,4-Dihydroxyphenylalanine Administration in SH-SY5Y Neuronal Cells

Yang, Z., Wang, X., Yang, J., Sun, M., Wang, X., & Wang, X. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9686-5 · Cited by 8 · see citing works

Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?

Li, D., Mastaglia, F. L., Yau, W. Y., Chen, S., Wilton, S. D., & Akkari, P. A. (2022) · Movement Disorders · doi:10.1002/mds.29201 · Cited by 8 · see citing works

Targeting Neurodegeneration: The Emerging Role of Hybrid Drugs

Deb, D., Dhanawat, M., Bhushan, B., Pachuau, L., & Das, N. (2025) · Current Drug Targets · doi:10.2174/0113894501365588250131073304 · Cited by 7 · see citing works

Focused ultrasound: focused on tremor

Davidson, B., & Lozano, A. M. (2025) · Expert Review of Medical Devices · doi:10.1080/17434440.2025.2489493 · Cited by 7 · see citing works

Modulation of Electron Transport via Target Recognition in Asymmetric Nanochannel Arrays for Enantiomer Detection

Shang, X., Yang, M. J., Su, T., Guo, J., Zhao, C. X., Song, P., Song, Y., & Li, Y. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c02831 · Cited by 7 · see citing works

Molecular Variability in Levodopa Absorption and Clinical Implications for the Management of Parkinson’s Disease

de Menezes, A. L. P., Bloem, B. R., Beckers, M., Piat, C., Benarroch, E. E., & Savica, R. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240036 · Cited by 7 · see citing works

A Novel NOX Inhibitor Alleviates Parkinson’s Disease Pathology in PFF-Injected Mice

Ofori, K., Ghosh, A., Verma, D., Wheeler, D., Cabrera, G. N., Seo, J. B., & Kim, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814278 · Cited by 6 · see citing works

Repeated treatments with the D1 dopamine receptor agonist SKF-38393 modulate cell viability via sustained ERK–Bad–Bax activation in dopaminergic neuronal cells

Park, H. J., Zhao, T. T., Park, K. H., & Lee, M. K. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.03.035 · Cited by 6 · see citing works

Synthetic aporphine alkaloids are potential therapeutics for Leigh syndrome

Kobayashi, M., Miyauchi, A., Jimbo, E. F., Oishi, N., Aoki, S., Watanabe, M., Yoshikawa, Y., Akiyama, Y., Yamagata, T., & Osaka, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-62445-w · Cited by 5 · see citing works

Calcium Channels and Selective Neuronal Vulnerability in Parkinson’s Disease

Liss, B., & Surmeier, D. J. (2022) · Springer eBooks · doi:10.1007/978-3-031-08881-0_22 · Cited by 5 · see citing works

Reductase-catalyzed tetrahydrobiopterin regeneration alleviates the anti-competitive inhibition of tyrosine hydroxylation by 7,8-dihydrobiopterin

Xu, Y., Li, Y., Li, L., Zhang, L., Ding, Z., & Shi, G. (2021) · Catalysis Science & Technology · doi:10.1039/d0cy01958e · Cited by 5 · see citing works

D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II

Gori, S. S., Thomas, A. G., Pal, A., Wiseman, R., Ferraris, D. V., Gao, R.-D., Wu, Y., Alt, J., Tsukamoto, T., Slusher, B. S., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102018 · Cited by 5 · see citing works

Nutrition in Parkinson’s disease: what neurologists need to know

Shuler, M. G. H., Prasad, A., Flanagan, R., Dayal, V., & Lithander, F. E. (2026) · Practical Neurology · doi:10.1136/pn-2025-004998 · Cited by 5 · see citing works

Vindeburnol: A natural product-inspired chemical tool for central nervous system drug design

Egorova, A., Zubkov, E. A., & Makarov, V. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116966 · Cited by 4 · see citing works

Extraction optimization of anti-Parkinson’s medication L-DOPA and bioactive compounds from Mucuna atropurpurea (Roxb.) Wight & Arn. with biomedical potential: RSM based desirability function approach

Mali, P., Kamble, P. P., Aware, C. B., Suryawanshi, S. S., & Jadhav, J. P. (2022) · Journal of Applied Research on Medicinal and Aromatic Plants · doi:10.1016/j.jarmap.2022.100451 · Cited by 4 · see citing works

Nanocarriers-Assisted Nose-to-Brain Delivery of Levodopa: Current Progress and Prospects

Dangova, M., Ivanova, N. A., & Andonova, V. (2024) · Applied Sciences · doi:10.3390/app15010331 · Cited by 4 · see citing works

Biomaterials and Stem Cells as Drug/Gene-Delivery Vehicles for Parkinson’s Treatment: An Update

Roshani, M., Kiaie, N., & Aghdam, R. M. (2021) · Regenerative Medicine · doi:10.2217/rme-2021-0050 · Cited by 4 · see citing works

From small to tall: breed-varied household pet dogs can be trained to detect Parkinson’s Disease

Holt, L., & Johnston, S. V. (2024) · Animal Cognition · doi:10.1007/s10071-024-01902-5 · Cited by 3 · see citing works

Deciphering Dual Modes of Parkinsonian Biomolecules Derived Fluorescent Nanoparticles: Protein Specificity and White Light Generation

Pyne, A., Nandi, P. K., Layek, S., Bera, N., Hazra, R., & Sarkar, N. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.2c01190 · Cited by 3 · see citing works

The Role of Next Generation Sequencing in Diagnosis of Brain Tumors: A Review Study

Shirian, S., Daneshbod, Y., Jangjoo, S., Ghaemi, A., Goodarzi, A., Ghavideldarestani, M., Emadi, A., Ai, A., Ahmadi, A., & Ai, J. (2019) · Archives of Neuroscience · doi:10.5812/ans.68874 · Cited by 3 · see citing works

Mechanical Forces Guide Axon Growth through the Nigrostriatal Pathway in an Organotypic Model

Vincentiis, S. D., Capitanini, E., Kira, K., Dell’Amico, C., Takahashi, J., Onorati, M., Raudzus, F., & Raffa, V. (2025) · Advanced Science · doi:10.1002/advs.202500400 · Cited by 2 · see citing works

Tissue response to deep brain stimulation electrodes: a review of animal and neurohistopathological studies

Zhao, D. X., Green, A. L., & Purcell, E. K. (2025) · Journal of Neural Engineering · doi:10.1088/1741-2552/adf669 · Cited by 3 · see citing works

Parkinson’s Disease: A Comprehensive Overview of the Disease

Khatib, A. J. A. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109437 · Cited by 2 · see citing works

Monitoring levodopa oxidation and reduction reactions using surface plasmon resonance on a nanohole array electrode

Peng, H.-F., Chang, C. C., Gupta, R. K., & Huang, J. (2023) · Discover Nano · doi:10.1186/s11671-023-03930-5 · Cited by 2 · see citing works

Cholestatic liver disease leads to significant adaptative changes in neural circuits regulating social behavior in mice to enhance sociability

Almishri, W., Altonsy, M. O., & Swain, M. G. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167100 · Cited by 1 · see citing works

Treatment of Parkinson's Disease

Nandanwar, D., & Truong, D. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00150-0 · Cited by 1 · see citing works

Long-term Probiotics Intervention Facilitates Recovery of Motor and Non-motor Functions by Regulating Inflammation and Modulating Gut-brain Axis in 6-OHDA Rat Model of Parkinson’s Disease

Sharma, S., Jain, S., Chittora, R., Chaudhry, R., Nag, T. C., Elavarasi, A., Radhakrishnan, D. M., Pandey, S., Das, S., Bamola, V. D., et al. (2025) · Annals of Neurosciences · doi:10.1177/09727531251335746 · Cited by 1 · see citing works

Understanding the experience of prescription charges in people living with parkinson’s disease: a focus group study

Readman, M. R., Oluseye, A., Brighton, L. J., Polden, M., Fairman, I., Parkinson, I., Parkinson, C., & Giebel, C. M. (2025) · BMC Public Health · doi:10.1186/s12889-025-24121-0 · Cited by 1 · see citing works

'Blind men and an elephant', the need for animals in research and drug safety studies in developing countries.Preprint

Anbalagan, S. (2023) · doi:10.31219/osf.io/dwsvt · Cited by 1 · see citing works

A biointegrated living brain stimulator evokes specific neural signallingPreprint

Zhao, Q., Meng, Q., Peng, M., Lu, Z., Liu, Z. H., Jiang, X., Zheng, H., & Du, X. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.22.725279 · Cited by 1 · see citing works

Étude de la vasoréactivité cérébrale par IRM fonctionnelle BOLD dans la maladie de Parkinson avant et après traitement par L-Dopa

Sahin, M. A. (2012) · OpenGrey (Institut de l'Information Scientifique et Technique)

Food consumption in patients with Parkinson's disease and its impact on disease prognosis and drug therapy

de Sousa, D. Z., Pacheco, A. C. L., Cerqueira, G. S., Ferreira, P. M. P., Peron, A. P., & Calou, I. B. F. (2014) · Boletim Informativo Geum

MODIFICATION OF APLYSIA FEEDING NETWORK BY L-DOPA AND DOPAMINE-DEPENDENT LEARNING

Neveu, C. L. (2017) · Digital Commons-TMC (Texas Medical Center)

Identifying neuron clusters controlling movement vigor

Strabinick, J. A. (2021)

Parkinson’s Disease - Animal Models, Current Therapies and Clinical Trials

Yenisetti, S. C., Koza, Z., Kumar, D., Singh, S. K., & Ganeshpurkar, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100831

Characterization of the Phosphomimetic Mutant Y39E of a-Synuclein

Böffinger, N. M. (2024) · doi:10.53846/goediss-10640

Parkinson's disease: treatment

(2000) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2000.20000925 · Cited by 8 · see citing works

Classics in Chemical Neuroscience: Levodopa

Whitfield, A. C., Moore, B. T., & Daniels, R. N. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5001759 · Cited by 68 · see citing works

- Treatment of Early Parkinson’s Disease

Pfeiffer, R. F., Wszolek, Z. K., & Ebadi, M. (2012) · CRC Press eBooks · doi:10.1201/b12948-60

Levodopa for the Treatment of Parkinson's Disease

LeWitt, P. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0800326 · Cited by 316 · see citing works

History of levodopa and dopamine agonists in Parkinson's disease treatment

TOLOSA, E. S., Martı́, M. J., Valldeoriola, F., & Molinuevo, J. L. (1998) · Neurology · doi:10.1212/wnl.50.6_suppl_6.s2 · Cited by 140 · see citing works